Sars-cov-2 nucleocapsid antibodies
AssigneeRoche Diagnostics Operations, Inc.
InventorsMichael Gerg, Ute Jucknischke, Ulrike Kurtkaya, Thomas Mock, Michael Schraeml, Sandrine Carolina Stiegler
Life of this patent
Estimating the term…
Abstract
The present invention relates to monoclonal antibodies binding to the nucleocapsid protein of SARS-CoV-2 virus, nucleic acids encoding said antibody, host cells producing the same, compositions and kits comprising said antibodies, as well as methods of detecting SARS-CoV-2 virus in a sample comprising using said antibodies.
Claims18
An isolated monoclonal antibody or antigen-binding fragment thereof that binds to the nucleocapsid protein of SARS-CoV-2 virus
- a) with an association rate constant (ka) of more than 1.0E+05 M−1 s−1, as determined by surface plasmon resonance,
- and/or
- b) with a dissociation rate constant (kd) of less than 5.0E-04 s−1, as determined by surface plasmon resonance,
- and/or
- c) with a half-life time of t/2diss of 15 minutes or more, as determined by surface plasmon resonance,
- and/or
- d) with a 1:1 or 1:2 stoichiometry.
(canceled)
An in vitro method for detecting the presence of SARS-CoV-2 virus in a sample obtained from a patient, comprising
- a) contacting the sample with at least one antibody or antibody binding fragment thereof which binds to the nucleocapsid of SARS-CoV-2, thereby generating a complex between the antibody and the nucleocapsid of SARS-CoV-2,
- b) optionally immobilizing the formed complexes to a solid phase, and
- c) detecting the presence of SARS-CoV-2 virus in the sample.
Dependencies are inferred from the claim text.